Ceribell, Inc. Files 8-K

Ticker: CBLL · Form: 8-K · Filed: Dec 9, 2025 · CIK: 1861107

Ceribell, INC. 8-K Filing Summary
FieldDetail
CompanyCeribell, INC. (CBLL)
Form Type8-K
Filed DateDec 9, 2025
Risk Levellow
Pages1
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k

Related Tickers: CBLL

TL;DR

Ceribell filed an 8-K on 12/9/25. Details TBD.

AI Summary

Ceribell, Inc. filed an 8-K on December 9, 2025, to report other events and financial statements. The filing does not contain specific details about the nature of these events or financial figures within the provided text.

Why It Matters

This filing indicates Ceribell, Inc. is making a regulatory submission to the SEC, which could contain important updates about the company's operations or financial status.

Risk Assessment

Risk Level: low — The filing is a standard procedural document without immediate disclosed financial impact or significant corporate changes.

Key Players & Entities

FAQ

What specific events are being reported in this 8-K filing by Ceribell, Inc.?

The provided text indicates the filing is for 'Other Events' and 'Financial Statements and Exhibits' but does not specify the details of these events.

When was the earliest event reported in this 8-K filing?

The earliest event reported is dated December 09, 2025.

What is Ceribell, Inc.'s principal executive office address?

Ceribell, Inc.'s principal executive offices are located at 360 N. Pastoria Avenue, Sunnyvale, California, 94085.

What is Ceribell, Inc.'s Commission File Number?

Ceribell, Inc.'s Commission File Number is 001-42364.

What is the SIC code for Ceribell, Inc.?

The Standard Industrial Classification (SIC) code for Ceribell, Inc. is 3845, which corresponds to ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS.

Filing Stats: 419 words · 2 min read · ~1 pages · Grade level 10.3 · Accepted 2025-12-09 09:16:18

Key Financial Figures

Filing Documents

01

Item 8.01 Other Events. On December 9, 2025, Ceribell, Inc. ("Ceribell") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") granted 510(k) clearance for Ceribell's proprietary delirium screening and monitoring solution. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release dated December 9, 2025. 104 Cover Page Interactive Data File, formatted in Inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CERIBELL, INC. Date: December 9, 2025 By: /s/ Scott Blumberg Scott Blumberg Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing